BidaskClub upgraded shares of Surgery Partners (NASDAQ:SGRY) from a buy rating to a strong-buy rating in a research report report published on Wednesday.
A number of other research firms have also weighed in on SGRY. Zacks Investment Research lowered Surgery Partners from a hold rating to a sell rating in a research report on Wednesday, March 14th. Jefferies Group set a $18.00 price target on Surgery Partners and gave the company a buy rating in a research report on Thursday, March 1st. Benchmark set a $19.00 price target on Surgery Partners and gave the company a buy rating in a research report on Tuesday, January 30th. Stifel Nicolaus decreased their price target on Surgery Partners from $17.00 to $15.00 and set a sell rating for the company in a research report on Tuesday, April 10th. Finally, ValuEngine lowered Surgery Partners from a hold rating to a sell rating in a research report on Friday, February 2nd. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Surgery Partners has a consensus rating of Hold and a consensus target price of $18.29.
Surgery Partners opened at $19.75 on Wednesday, MarketBeat Ratings reports. The stock has a market cap of $956.24 million, a P/E ratio of -23.51 and a beta of 1.85. Surgery Partners has a 52-week low of $19.50 and a 52-week high of $19.90. The company has a current ratio of 1.72, a quick ratio of 1.55 and a debt-to-equity ratio of 1.63.
Surgery Partners (NASDAQ:SGRY) last released its earnings results on Wednesday, May 9th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). The firm had revenue of $417.37 million for the quarter, compared to analyst estimates of $410.79 million. Surgery Partners had a negative return on equity of 1.90% and a negative net margin of 5.13%. Surgery Partners’s revenue was up 45.8% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.06) earnings per share. sell-side analysts anticipate that Surgery Partners will post -0.26 earnings per share for the current fiscal year.
Several large investors have recently added to or reduced their stakes in the stock. Millennium Management LLC acquired a new position in shares of Surgery Partners in the 1st quarter valued at $814,000. Point72 Asset Management L.P. acquired a new position in shares of Surgery Partners in the 1st quarter valued at $6,097,000. MetLife Investment Advisors LLC acquired a new position in shares of Surgery Partners in the 1st quarter valued at $164,000. GSA Capital Partners LLP acquired a new position in shares of Surgery Partners in the 1st quarter valued at $222,000. Finally, BNP Paribas Arbitrage SA boosted its position in shares of Surgery Partners by 2,564.5% in the 1st quarter. BNP Paribas Arbitrage SA now owns 104,021 shares of the company’s stock valued at $1,784,000 after purchasing an additional 100,117 shares during the period.
Surgery Partners Company Profile
Surgery Partners, Inc is healthcare services holding company, which engages in the provision of solutions for surgical and related ancillary care in support of its patients and physicians. It operates through the following business segments: Surgical Facility Services; Ancillary Services; and Optical Services.
Receive News & Ratings for Surgery Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surgery Partners and related companies with MarketBeat.com's FREE daily email newsletter.